TL;DR: The Centers for Medicare & Medicaid Services modified NCD 88, its psoriasis treatment coverage policy, effective March 7, 2026. Here's what billing teams need to know.
CMS psoriasis treatment coverage policy under NCD 88 in the Medicare system has been updated. The change clarifies coverage criteria for conventional psoriasis treatments and PUVA therapy — and sets hard limits on reimbursement duration and amount. No specific CPT or HCPCS codes are listed in the policy document itself, but the clinical and documentation requirements directly affect how you build your claims and what your Medicare Administrative Contractor will accept.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Treatment of Psoriasis |
| Policy Code | NCD 88 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Dermatology, primary care, phototherapy centers |
| Key Action | Confirm MAC documentation of conventional treatment failure before billing PUVA therapy, and cap PUVA claims at 30 treatment days unless improvement is documented |
CMS Psoriasis Treatment Coverage Criteria and Medical Necessity Requirements 2026
NCD 88 is the National Coverage Determination governing Medicare coverage of psoriasis treatment. It covers both conventional therapies and the newer PUVA approach — but with a strict step-therapy structure that determines medical necessity at each stage.
For conventional treatments, Medicare coverage is straightforward. Three approaches qualify: topical application of steroids or other drugs, ultraviolet light therapy (actinotherapy), and coal tar alone or in combination with ultraviolet B light (the Goeckerman treatment). These don't require a failure-to-respond trigger — they're covered as primary treatment options.
PUVA therapy is different. PUVA combines a psoralen derivative drug with ultraviolet A light. Medicare covers PUVA only for intractable, disabling psoriasis — and only after conventional treatments have failed. That sequencing requirement is not optional.
The real issue here is the documentation burden before you bill. Your Medicare Administrative Contractor must document the failure of conventional treatment before paying for PUVA. That means the responsibility to establish and preserve that documentation trail sits with your billing and clinical teams — not with the MAC after the fact. Missing or thin documentation is the fastest path to a claim denial.
The coverage policy also sets a reimbursement ceiling for PUVA: payment is limited to what CMS pays for other types of photochemotherapy. You're not getting a premium rate for PUVA just because it's a newer approach. And the standard PUVA course is capped at 30 days of treatment — with documented improvement required to extend beyond that.
Prior authorization is not explicitly called out in this policy. However, the MAC documentation requirement before payment functions as a de facto pre-approval gatekeeping step. If you're not sure whether your MAC interprets this as requiring formal prior authorization, contact them directly before the effective date of March 7, 2026.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Topical steroid or drug application for psoriasis | Covered | Not specified in policy | Standard primary treatment; no step-therapy required |
| Ultraviolet light therapy (actinotherapy) for psoriasis | Covered | Not specified in policy | Covered as conventional treatment |
| Coal tar treatment alone for psoriasis | Covered | Not specified in policy | Covered as conventional treatment |
| Coal tar with ultraviolet B light (Goeckerman treatment) | Covered | Not specified in policy | Covered as conventional treatment |
| PUVA therapy for intractable, disabling psoriasis — after conventional treatment failure | Covered (with conditions) | Not specified in policy | MAC must document conventional treatment failure before payment; capped at 30 treatment days unless improvement is documented; reimbursement limited to photochemotherapy rate |
| PUVA therapy without documented conventional treatment failure | Not Covered | Not specified in policy | Step-therapy requirement not met; claim denial likely |
| PUVA therapy beyond 30 days without documented improvement | Not Covered | Not specified in policy | Extended treatment requires documented clinical improvement |
CMS Psoriasis Billing Guidelines and Action Items 2026
The billing guidelines under NCD 88 are more procedural than clinical. The coverage criteria aren't complicated — but the documentation and sequencing requirements are where claims fall apart. Here's what to do before March 7, 2026.
| # | Action Item |
|---|---|
| 1 | Audit your PUVA claims workflow now. Pull every active PUVA patient file and confirm that each chart documents a failure of conventional treatment — topical steroids, actinotherapy, or coal tar/UVB. If you can't show prior conventional treatment failure, your claim lacks the medical necessity foundation the MAC requires. |
| 2 | Confirm your MAC's documentation standards. NCD 88 says the MAC "should document" conventional treatment failure before paying for PUVA. Call or check your MAC's website to find out exactly what they require — a physician attestation, clinical notes, a specific timeframe. Don't assume your current documentation format is sufficient. |
| 3 | Set a 30-day treatment counter for every PUVA patient. Build this into your practice management system or billing workflow. At day 30, your billing team needs a documented improvement note from the treating physician before submitting claims for continued PUVA therapy. No improvement note, no reimbursement — it's that simple. |
| 4 | Check your PUVA reimbursement rates against photochemotherapy. The policy caps PUVA reimbursement at the rate paid for other photochemotherapy types. If your charge capture or fee schedule has PUVA priced higher than that benchmark, adjust it. Overbilling above the allowed rate creates overpayment liability. |
| 5 | Don't skip billing for conventional treatments in step-therapy sequences. If you're treating a patient who will eventually need PUVA, bill the conventional treatments you've actually provided. That claim history supports the medical necessity argument for PUVA later — and it's accurate billing. |
| 6 | Flag psoriasis treatment billing for a compliance review. The step-therapy structure here means the order of claims matters as much as the codes themselves. Talk to your compliance officer before March 7, 2026 if your practice has high PUVA volume. A compliance review of active PUVA cases is worth doing now, not after a MAC audit. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Psoriasis Treatment Under NCD 88
The policy document for NCD 88 does not list specific CPT, HCPCS, or ICD-10 codes. This is not unusual for older NCDs that predate the current coding structure — but it creates a real problem for psoriasis billing.
What This Means for Your Billing Team
Without codes specified in the policy itself, you're working from MAC-level guidance and standard coding conventions for phototherapy and photochemotherapy. Your MAC may have a Local Coverage Determination (LCD) that maps specific codes to the NCD 88 criteria. Check with your MAC directly — most publish LCDs that supplement NCDs with code-level specifics.
For PUVA therapy billing, your coding team should confirm which HCPCS or CPT codes your MAC recognizes for psoralen drug administration and ultraviolet A phototherapy. The same goes for conventional treatments: actinotherapy, Goeckerman treatment, and topical drug administration each have coding pathways that your MAC will evaluate against NCD 88's step-therapy structure.
Finding the Right Codes
Contact your MAC or check their LCD database for codes mapped to psoriasis phototherapy and PUVA. The AMA CPT code set and HCPCS Level II include codes for phototherapy services — your billing consultant or coding staff should cross-reference those against your MAC's published guidance before the effective date.
If you're treating high volumes of psoriasis patients and don't have a clear code-to-policy mapping documented, that's a gap worth closing now. Talk to your billing consultant about building a psoriasis treatment code matrix tied to NCD 88's step-therapy criteria before March 7, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.